These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32396404)

  • 1. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?
    Sobhani N; Corona SP; Roviello G; Bagby S; D'Angelo A; Iezzi G; Generali D
    Future Oncol; 2020 Jul; 16(19):1327-1330. PubMed ID: 32396404
    [No Abstract]   [Full Text] [Related]  

  • 2. How to select cancer patients for immunotherapy.
    Pfeiffer P; Qvortrup C; Hansen KH
    EBioMedicine; 2021 Jan; 63():103184. PubMed ID: 33418504
    [No Abstract]   [Full Text] [Related]  

  • 3. Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells.
    Liu M; Zhao Z; Wang C; Sang S; Cui Y; Lv C; Yang X; Zhang N; Xiong K; Chen B; Dong Q; Liu K; Gu Y
    Cancer Lett; 2024 Jul; 594():216991. PubMed ID: 38797232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors.
    Benitez JC; Recondo G; Rassy E; Mezquita L
    Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):162-174. PubMed ID: 32107903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review.
    Dijkstra KK; Voabil P; Schumacher TN; Voest EE
    JAMA Oncol; 2016 Nov; 2(11):1490-1495. PubMed ID: 27491050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in cancer immunotherapy.
    Himmel ME; Saibil SD; Saltman AP
    CMAJ; 2020 Jun; 192(24):E651. PubMed ID: 32540906
    [No Abstract]   [Full Text] [Related]  

  • 7. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.
    Wang X; Wang F; Zhong M; Yarden Y; Fu L
    Mol Cancer; 2020 May; 19(1):81. PubMed ID: 32359357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic basis for response to cancer immunotherapy.
    Gruber K
    Lancet Oncol; 2017 Sep; 18(9):e521. PubMed ID: 28826592
    [No Abstract]   [Full Text] [Related]  

  • 10. Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations.
    Riudavets M; Auclin E; Mezquita L
    Future Oncol; 2020 Aug; 16(23):1665-1668. PubMed ID: 32422071
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade.
    Barragan I
    EBioMedicine; 2020 Oct; 60():103005. PubMed ID: 32987318
    [No Abstract]   [Full Text] [Related]  

  • 13. Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.
    Sinha N; Sinha S; Cheng K; Madan S; Erez A; Ryan BM; Schäffer AA; Aldape K; Ruppin E
    JCO Precis Oncol; 2021 Nov; 5():1147-1150. PubMed ID: 34994632
    [No Abstract]   [Full Text] [Related]  

  • 14. Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.
    Sidders B; Zhang P; Goodwin K; O'Connor G; Russell DL; Borodovsky A; Armenia J; McEwen R; Linghu B; Bendell JC; Bauer TM; Patel MR; Falchook GS; Merchant M; Pouliot G; Barrett JC; Dry JR; Woessner R; Sachsenmeier K
    Clin Cancer Res; 2020 May; 26(9):2176-2187. PubMed ID: 31953314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
    Wilky BA
    Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
    Davoli T; Uno H; Wooten EC; Elledge SJ
    Science; 2017 Jan; 355(6322):. PubMed ID: 28104840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic melanoma: therapeutic agents in preclinical and early clinical development.
    Boos LA; Leslie I; Larkin J
    Expert Opin Investig Drugs; 2020 Jul; 29(7):739-753. PubMed ID: 32401070
    [No Abstract]   [Full Text] [Related]  

  • 20. Status of Immune Oncology: Challenges and Opportunities.
    Cesano A; Marincola FM; Thurin M
    Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.